But SGLT2 inhibitors have recently been linked to 20 cases of diabetic ketoacidosis (DKA), as noted in a May 15 drug safety communication from the FDA. ... A patient who knows you will update them as information accumulates is a partner in understanding
with the drug are likely to outweigh its potential risks for each patient. ... Approved on the fast track as an orphan drug, safety and efficacy were evaluated in 4 clinical trials including 547 treated patients.
dose should exceed 16 mg, according to the agency's drug safety communication online. ... The FDA is continuing to evaluate multiple sources of data in the ongoing safety review of this issue but has not changed its recommendations regarding the drug.
A labeling update and drug safety communication on low-molecular-weight heparin, including enoxaparin, regarding the risk of spinal column bleeding and subsequent paralysis after spinal injections, including epidural procedures and ... Safety and
When meeting with Rep. Earl Blumenauer (D-OR), Ms. Blank and ACP Resident/Fellow Member Joel Burnett, MD, led discussions on prescription drug pricing and physician workforce issues. ... with that,” although the downside is potentially compromised drug
A warning about drug interactions between boceprevir (Victrelis) and ritonavir-boosted HIV protease inhibitor drugs. ... However, the FDA continues to believe that the cardiovascular benefits of statins outweigh these small increased risks, according to
It's also recommended that clinicians discontinue the drug in patients with symptoms of liver injury. ... A drug safety communication about the risk of name confusion between ado-trastuzumab emtansine (Kadcyla) and trastuzumab (Herceptin).
The drug's safety and efficacy were evaluated in a clinical trial with more than 14,000 patients, in which it showed similar ability to warfarin in preventing stroke. ... Given the conflicting nature of the existing research findings on this issue, the
Photo by ThinkStock. A drug safety communication that canagliflozin (Invokana, Invokamet) causes an increased risk of leg and foot amputations. ... A drug safety communication about gadolinium-based contrast agents for MRI. An FDA review, initiated in
Caleb Alexander, MD, co-director of the Johns Hopkins School of Public Health Center for Drug Safety and Effectiveness in Baltimore. ... educated about the risks and benefits and if you can effectively monitor for safety.